Corient Private Wealth LP Takes $3.11 Million Position in Omada Health, Inc. $OMDA

Corient Private Wealth LP acquired a new stake in Omada Health, Inc. (NASDAQ:OMDA) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 141,592 shares of the company’s stock, valued at approximately $3,108,000.

Other large investors have also bought and sold shares of the company. Raymond James Financial Inc. acquired a new stake in Omada Health during the 2nd quarter worth approximately $32,000. Bellevue Group AG boosted its holdings in shares of Omada Health by 0.7% in the third quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock valued at $5,567,000 after buying an additional 1,791 shares during the period. Quarry LP acquired a new position in shares of Omada Health in the fourth quarter valued at approximately $29,000. Barclays PLC increased its position in shares of Omada Health by 14.6% during the fourth quarter. Barclays PLC now owns 14,850 shares of the company’s stock worth $234,000 after acquiring an additional 1,888 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in shares of Omada Health by 319.3% during the second quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock worth $66,000 after acquiring an additional 2,283 shares in the last quarter.

Omada Health Stock Down 7.0%

NASDAQ OMDA opened at $22.84 on Wednesday. The firm’s 50 day moving average is $22.50 and its 200-day moving average is $17.38. The company has a market capitalization of $1.40 billion, a PE ratio of 456.80 and a beta of 1.85. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $26.92.

Omada Health (NASDAQ:OMDA) last announced its earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.10. The business had revenue of $87.83 million during the quarter, compared to analysts’ expectations of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. As a group, sell-side analysts expect that Omada Health, Inc. will post 0.09 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on OMDA. Barclays boosted their price objective on shares of Omada Health from $20.00 to $25.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Citizens Jmp increased their target price on Omada Health from $27.00 to $32.00 and gave the stock a “market outperform” rating in a report on Friday, August 14th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Omada Health in a research note on Friday, May 8th. Wells Fargo & Company boosted their price target on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Finally, Evercore reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Omada Health in a research report on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Omada Health has a consensus rating of “Moderate Buy” and a consensus target price of $26.50.

Insider Buying and Selling at Omada Health

In other Omada Health news, CEO Sean P. Duffy sold 12,942 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $24.81, for a total transaction of $321,091.02. Following the sale, the chief executive officer directly owned 411,861 shares of the company’s stock, valued at $10,218,271.41. The trade was a 3.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, President Wei-Li Shao sold 8,866 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $25.02, for a total transaction of $221,827.32. Following the transaction, the president owned 307,372 shares of the company’s stock, valued at approximately $7,690,447.44. This represents a 2.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 255,834 shares of company stock valued at $5,398,196. Corporate insiders own 6.38% of the company’s stock.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.